Quercetin in prostate cancer: Chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential (review)

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2659-2668

  Yang, Feiya ^a   Song, Liming ^a   Wang, Huiping ^b   Wang, Jun ^c   Xu, Zhiqing ^d   Xing, Nianzeng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chemoprevention; Chemotherapy; Clinical application potential; Effect; Mechanisms; Prostate cancer; Quercetin

Indexed keywords

ANDROGEN RECEPTOR; CATALASE; CYCLIN D1; CYCLIN E; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; FATTY ACID; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; QUERCETIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; DIET THERAPY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; GENETICS; MALE; PATHOLOGY; PROSTATIC NEOPLASMS;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUERCETIN;

EID: 84928905615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3886     Document Type: Article

References (111)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC and Wang Y: Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol 8: 311-322, 2014.
3. Xing N, Chen Y, Mitchell SH and Young CY: Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22: 409-414, 2001.
4. Wang G, Song L, Wang H and Xing N: Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells. Oncol Rep 30: 357-363, 2013.
5. Sharmila G, Bhat FA, Arunkumar R, Elumalai P, Raja Singh P, Senthilkumar K and Arunakaran J: Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clin Nutr 33: 718-726, 2014.
6. Firdous AB, Sharmila G, Balakrishnan S, RajaSingh P, Suganya S, Srinivasan N and Arunakaran J: Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway. Food Funct 5: 2632-2645, 2014.
7. Sharmila G, Athirai T, Kiruthiga B, Senthilkumar K, Elumalai P, Arunkumar R and Arunakaran J: Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of Sprague-Dawley rats. Nutr Cancer 66: 38-46, 2014.
8. Fleshner N: Defining high-risk prostate cancer: current status Can J Urol (Suppl 1): 14-96, 2005.
9. Hotte SJ and Saad F: Current management of castrate-resistant prostate cancer. Curr Oncol 17 (Suppl 2): S72-S79, 2010.
10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
11. Antonarakis ES and Eisenberger MA: Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 31: 1709-1712, 2013.
12. McKeage K: Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs 72: 1559-1577, 2012.
13. Bischoff SC: Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 11: 733-740, 2008.
14. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H and Veit M: Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41: 492-499, 2001.
15. Walle T, Otake Y, Walle UK and Wilson FA: Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr 130: 2658-2661, 2000.
16. Russo GL, Russo M and Spagnuolo C: The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. Food Funct 5: 2393-2401, 2014.
17. Kim GT, Lee SH, Kim JI and Kim YM: Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int J Mol Med 33: 863-869, 2014.
18. Chan ST, Yang NC, Huang CS, Liao JW and Yeh SL: Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS One 8: e54255, 2013.
19. Piao S, Kang M, Lee YJ, Choi WS, Chun YS, Kwak C and Kim HH: Cytotoxic effects of escin on human castration-resistant prostate cancer cells through the induction of apoptosis and G2/M cell cycle arrest. Urology 84: 982.e1-7, 2014.
20. Mehta RG, Murillo G, Naithani R and Peng X: Cancer chemoprevention by natural products: how far have we come? Pharm Res 27: 950-961, 2010.
21. Liu KC, Yen CY, Wu RS, Yang JS, Lu HF, Lu KW, Lo C, Chen HY, Tang NY, Wu CC, et al: The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells. Environ Toxicol 29: 428-439, 2014.
22. Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T and Manne U: Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res 32: 61-71, 2012.
23. Kumar R, Verma V, Jain A, Jain RK, Maikhuri JP and Gupta G: Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J Nutr Biochem 22: 723-731, 2011.
24. Noori-Daloii MR, Momeny M, Yousefi M, Shirazi FG, Yaseri M, Motamed N, Kazemialiakbar N and Hashemi S: Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol 28: 1395-1404, 2011.
25. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE and Klotz LH: Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9: 68-76, 2006.
26. Knowles LM, Zigrossi DA, Tauber RA, Hightower C and Milner JA: Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 38: 116-122, 2000.
27. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 37: 223-233, 2000.
28. Vermeulen K, Van Bockstaele DR and Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol 84: 627-639, 2005.
29. Jung YH, Heo J, Lee YJ, Kwon TK and Kim YH: Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci 86: 351-357, 2010.
30. Kim YH, Lee DH, Jeong JH, Guo ZS and Lee YJ: Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 75: 1946-1958, 2008.
31. Kim YH and Lee YJ: TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 100: 998-1009, 2007.
32. Lee DH, Szczepanski M and Lee YJ: Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol 75: 2345-2355, 2008.
33. Senthilkumar K, Elumalai P, Arunkumar R, Banudevi S, Gunadharini ND, Sharmila G, Selvakumar K and Arunakaran J: Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem 344: 173-184, 2010.
34. Xu R, Zhang Y, Ye X, Xue S, Shi J, Pan J and Chen Q: Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro. Food Chem 138: 48-53, 2013.
35. Wang P, Heber D and Henning SM: Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr Cancer 64: 580-587, 2012.
36. Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Aruldhas MM and Arunakaran J: Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol 131: 765-771, 2005.
37. Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB and Macdonald RS: Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 49: 200-208, 2004.
38. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G and Klocker H: Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40: 241-251, 2001.
39. Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170, 2002.
40. Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186, 2009.
41. Culig Z and Bartsch G: Androgen axis in prostate cancer. J Cell Biochem 99: 373-381, 2006.
42. Yuan H, Young CY, Tian Y, Liu Z, Zhang M and Lou H: Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem 339: 253-262, 2010.
43. Ferruelo A, Romero I, Cabrera PM, Arance I, Andrés G and Angulo JC: Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. Actas Urol Esp 38: 397-404, 2014.
44. Yuan H, Pan Y and Young CYF: Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 213: 155-163, 2004.
45. Yuan HQ, Guo HF, He ML, Kong F, Hu XY, Jiang AL, Xu X, Zhang JY and Charles YF: The roles of c-Jun and CBP in the inhibitory effect of quercetin on prostate cancer cells. Yao Xue Xue Bao 41: 819-824, 2006 (In Chinese).
46. Yuan H, Gong A and Young CY: Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26: 793-801, 2005.
47. Britton RG, Horner-Glister E, Pomenya OA, Smith EE, Denton R, Jenkins PR, Steward WP, Brown K, Gescher A and Sale S: Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents. Eur J Med Chem 54: 952-958, 2012.
48. Hsieh TC and Wu JM: Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res 29: 4025-4032, 2009.
49. Morris JD, Pramanik R, Zhang X, Carey AM, Ragavan N, Martin FL and Muir GH: Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett 239: 111-122, 2006.
50. Morgan TM, Koreckij TD and Corey E: Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9: 237-249, 2009.
51. Cohen MB and Rokhlin OW: Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 106: 363-371, 2009.
52. Baiz D, Pinder TA, Hassan S, Karpova Y, Salsbury F, Welker ME and Kulik G: Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug. J Med Chem 55: 8038-8046, 2012.
53. Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.
54. Yu PC, Gu SY, Bu JW and Du JL: TRPC1 is essential for in vivo angiogenesis in zebrafish. Circ Res 106: 1221-1232, 2010.
55. Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell 146: 873-887, 2011.
56. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
57. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
58. Oh SJ, Kim O, Lee JS, Kim JA, Kim MR, Choi HS, Shim JH, Kang KW and Kim YC: Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. Food Chem Toxicol 48: 3227-3234, 2010.
59. Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C and Sidor C: Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 115: 90-96, 2009.
60. Chen Y, Li XX, Xing NZ and Cao XG: Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol 246: 373-378, 2008.
61. Lee DH and Lee YJ: Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105: 546-553, 2008.
62. Shimada M, Hernandez-Gonzalez I, Gonzalez-Robayna I and Richards JS: Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: key roles for prostaglandin synthase 2 and progesterone receptor. Mol Endocrinol 20: 1352-1365, 2006.
63. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999.
64. Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA and Luttrell LM: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162: 1537-1542, 1999.
65. Shimada K, Nakamura M, Ishida E, Kishi M and Konishi N: Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24: 1067-1075, 2003.
66. Senthilkumar K, Arunkumar R, Elumalai P, Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, Benson CS and Arunakaran J: Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct 29: 87-95, 2011.
67. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L and Pollak M: Insulin receptor expression by human prostate cancers. Prostate 69: 33-40, 2009.
68. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61: 6276-6280, 2001.
69. Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Dharmarajan A and Arunakaran J: Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3. Oncol Res 16: 67-74, 2006.
70. Vijayababu MR, Arunkumar A, Kanagaraj P and Arunakaran J: Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells. J Carcinog 5: 10, 2006.
71. Wang S, DeGroff VL and Clinton SK: Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 133: 2367-2376, 2003.
72. Bhat FA, Sharmila G, Balakrishnan S, Arunkumar R, Elumalai P, Suganya S, Raja Singh P, Srinivasan N and Arunakaran J: Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem 25: 1132-1139, 2014.
73. Tang SN, Singh C, Nall D, Meeker D, Shankar S and Srivastava RK: The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5: 14, 2010.
74. Ko CC, Chen YJ, Chen CT, Liu YC, Cheng FC, Hsu KC and Chow LP: Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells. J Biol Chem 289: 22078-22089, 2014.
75. Ferruelo A, de Las Heras MM, Redondo C, Ramón de Fata F, Romero I and Angulo JC: Wine polyphenols exert antineoplasic effect on androgen resistant PC-3 cell line through the inhibition of the transcriptional activity of COX-2 promoter mediated by NF-eκ B. Actas Urol Esp 38: 429-437, 2014 (In English and Spanish).
76. Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, MacDonald RS, Besch-Williford CL and Lubahn DB: Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res 70: 3382-3390, 2010.
77. Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R and Schwartz SA: Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol 11: 63-69, 2004.
78. Bandyopadhyay S, Romero JR and Chattopadhyay N: Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol 287: 57-64, 2008.
79. Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC and Schwartz SA: The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate 68: 1773-1789, 2008.
80. Jones EL, Zhao MJ, Stevenson MA and Calderwood SK: The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer. Int J Hyperthermia 20: 835-849, 2004.
81. Nakanoma T, Ueno M, Iida M, Hirata R and Deguchi N: Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells. Int J Urol 8: 623-630, 2001.
82. Asea A, Ara G, Teicher BA, Stevenson MA and Calderwood SK: Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia 17: 347-356, 2001.
83. Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataraman P, Krishnamoorthy G and Arunakaran J: Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem 287: 109-116, 2006.
84. Chaudhary A and Willett KL: Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. Toxicology 217: 194-205, 2006.
85. Brusselmans K, Vrolix R, Verhoeven G and Swinnen JV: Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 280: 5636-5645, 2005.
86. Huynh H, Nguyen TT, Chan E and Tran E: Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor α (TGF-α)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. Int J Oncol 23: 821-829, 2003.
87. Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH and Huynh H: Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol 24: 1297-1304, 2004.
88. Wang P, Vadgama JV, Said JW, Magyar CE, Doan N, Heber D and Henning SM: Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem 25: 73-80, 2014.
89. Ma Z, Hung Nguyen T, Hoa Huynh T, Tien Do P and Huynh H: Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. J Endocrinol 181: 493-507, 2004.
90. Xiao ZP, Peng ZY, Peng MJ, Yan WB, Ouyang YZ and Zhu HL: Flavonoids health benefits and their molecular mechanism. Mini Rev Med Chem 11: 169-177, 2011.
91. Szliszka E and Krol W: The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev 20: 63-69, 2011.
92. Leonarduzzi G, Testa G, Sottero B, Gamba P and Poli G: Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem 17: 74-95, 2010.
93. Klingeler R, Hampel S and Büchner B: Carbon nanotube based biomedical agents for heating, temperature sensoring and drug delivery. Int J Hyperther 24: 496-505, 2008.
94. Cirillo G, Vittorio O, Hampel S, Iemma F, Parchi P, Cecchini M, Puoci F and Picci N: Quercetin nanocomposite as novel anticancer therapeutic: improved efficiency and reduced toxicity. Eur J Pharm Sci 49: 359-365, 2013.
95. Forbes AM, Lin H, Meadows GG and Meier GP: Synthesis and anticancer activity of new flavonoid analogs and inconsistencies in assays related to proliferation and viability measurements. Int J Oncol 45: 831-842, 2014.
96. Paliwal S, Sundaram J and Mitragotri S: Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br J Cancer 92: 499-502, 2005.
97. Lund L, Svolgaard N and Poulsen MH: Prostate cancer: a review of active surveillance. Res Rep Urol 6: 107-112, 2014.
98. Sakr WA, Haas GP, Cassin BF, Pontes JE and Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385, 1993.
99. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
100. Ting H, Deep G, Agarwal C and Agarwal R: The strategies to control prostate cancer by chemoprevention approaches. Mutat Res Fundam Mol Mech Mutagen 760: 1-15, 2014.
101. Wang Z, Fan J, Liu M, Yeung S, Chang A, Chow MS, Pon D and Huang Y: Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application. Expert Opin Investig Drugs 22: 1613-1626, 2013.
102. Hsing AW, Tsao L and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85: 60-67, 2000.
103. Cook LS, Goldoft M, Schwartz SM and Weiss NS: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 161: 152-155, 1999.
104. Chaudhary A, Pechan T and Willett KL: Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. Toxicol Appl Pharmacol 220: 197-210, 2007.
105. Gugler R, Leschik M and Dengler HJ: Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9: 229-234, 1975.
106. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668, 1996.
107. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G and Mueller MJ: Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138: 1615-1621, 2008.
108. Utesch D, Feige K, Dasenbrock J, Broschard TH, Harwood M, Danielewska-Nikiel B and Lines TC: Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 654: 38-44, 2008.
109. Shoskes DA, Zeitlin SI, Shahed A and Rajfer J: Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 54: 960-963, 1999.
110. Cialdella-Kam L, Nieman DC, Sha W, Meaney MP, Knab AM and Shanely RA: Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults. Br J Nutr 109: 1923-1933, 2013.
111. McCann SE, Ambrosone CB, Moysich KB, Brasure J, Marshall JR, Freudenheim JL, Wilkinson GS and Graham S: Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in Western New York. Nutr Cancer 53: 33-41, 2005.